|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0016536,
umls-concept:C0018284,
umls-concept:C0027895,
umls-concept:C0030956,
umls-concept:C0042402,
umls-concept:C0079809,
umls-concept:C0205276,
umls-concept:C0205314,
umls-concept:C0231491,
umls-concept:C0232338,
umls-concept:C0242485,
umls-concept:C0381385,
umls-concept:C0679622,
umls-concept:C0871261,
umls-concept:C0920321,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1709518,
umls-concept:C2911692
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2001-10-11
|
|
pubmed:abstractText |
Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH(2) (Antagonist G), a substance P (SP 6-11) analogue, inhibits mitogenesis stimulated by a broad spectrum of neuropeptides and has demonstrated antitumor activity in vitro and in vivo with IC(50) concentrations of 10-20 microM in small cell lung cancer and other cell lines. Because neuropeptides are part of complex neurohumoral pathways, we have sought to develop novel pharmacodynamic approaches as part of the early clinical development of this potential anticancer drug.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3071-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11595697-Adult,
pubmed-meshheading:11595697-Aged,
pubmed-meshheading:11595697-Antineoplastic Agents,
pubmed-meshheading:11595697-Brachial Artery,
pubmed-meshheading:11595697-Bradykinin,
pubmed-meshheading:11595697-Dose-Response Relationship, Drug,
pubmed-meshheading:11595697-Female,
pubmed-meshheading:11595697-Flushing,
pubmed-meshheading:11595697-Forearm,
pubmed-meshheading:11595697-Humans,
pubmed-meshheading:11595697-Infusion Pumps,
pubmed-meshheading:11595697-Male,
pubmed-meshheading:11595697-Metabolic Clearance Rate,
pubmed-meshheading:11595697-Middle Aged,
pubmed-meshheading:11595697-Neoplasms,
pubmed-meshheading:11595697-Neuropeptides,
pubmed-meshheading:11595697-Oligopeptides,
pubmed-meshheading:11595697-Regional Blood Flow,
pubmed-meshheading:11595697-Substance P,
pubmed-meshheading:11595697-Treatment Outcome,
pubmed-meshheading:11595697-Vasodilator Agents
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist.
|
|
pubmed:affiliation |
Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, University of Edinburgh, Edinburgh EH4 2XU, Scotland, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
